Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Larotrectinib | 1223403-58-4 | 25 MG
Supplier: Medchemexpress LLC 25MGHY12866
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors (TRKA, B, and C), showing low nanomolar 50% inhibitory concentrations and high selectivity. It demonstrates dose-dependent inhibition of cell proliferation, with good oral bioavailability and plasma protein binding in preclinical studies. This compound effectively reduces TRKA phosphorylation and downstream signaling, leading to tumor growth inhibition in vivo and reduced leukemic infiltration.
- Selective inhibitor of TRK family receptors (TRKA, B, C)
- Low nanomolar inhibitory concentrations and high selectivity
- Dose-dependent inhibition of cell proliferation
- Good oral bioavailability and plasma protein binding
- Reduces TRKA phosphorylation and downstream signal transduction
- Inhibits tumor growth in vivo
- Reduces leukemic infiltration
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?